Pandemic vaccine testing: Combining conventional and challenge studies

Early into COVID, human challenge trials were considered, but usually as alternatives to conventional randomized controlled trials. Instead, assessment of authorized COVID vaccines, of further COVID vaccines, and of vaccines against future pandemics should combine both designs, in five different way...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerhard, Tobias, Strom, Brian L., Eyal, Nir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313872/
https://www.ncbi.nlm.nih.gov/pubmed/35297119
http://dx.doi.org/10.1002/pds.5429
_version_ 1784754180734320640
author Gerhard, Tobias
Strom, Brian L.
Eyal, Nir
author_facet Gerhard, Tobias
Strom, Brian L.
Eyal, Nir
author_sort Gerhard, Tobias
collection PubMed
description Early into COVID, human challenge trials were considered, but usually as alternatives to conventional randomized controlled trials. Instead, assessment of authorized COVID vaccines, of further COVID vaccines, and of vaccines against future pandemics should combine both designs, in five different ways, including a wholly novel one that we elaborate, Viz., combining data from both designs to answer a single question.
format Online
Article
Text
id pubmed-9313872
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-93138722022-07-30 Pandemic vaccine testing: Combining conventional and challenge studies Gerhard, Tobias Strom, Brian L. Eyal, Nir Pharmacoepidemiol Drug Saf Commentary Early into COVID, human challenge trials were considered, but usually as alternatives to conventional randomized controlled trials. Instead, assessment of authorized COVID vaccines, of further COVID vaccines, and of vaccines against future pandemics should combine both designs, in five different ways, including a wholly novel one that we elaborate, Viz., combining data from both designs to answer a single question. John Wiley & Sons, Inc. 2022-03-31 2022-06 /pmc/articles/PMC9313872/ /pubmed/35297119 http://dx.doi.org/10.1002/pds.5429 Text en © 2022 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Gerhard, Tobias
Strom, Brian L.
Eyal, Nir
Pandemic vaccine testing: Combining conventional and challenge studies
title Pandemic vaccine testing: Combining conventional and challenge studies
title_full Pandemic vaccine testing: Combining conventional and challenge studies
title_fullStr Pandemic vaccine testing: Combining conventional and challenge studies
title_full_unstemmed Pandemic vaccine testing: Combining conventional and challenge studies
title_short Pandemic vaccine testing: Combining conventional and challenge studies
title_sort pandemic vaccine testing: combining conventional and challenge studies
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313872/
https://www.ncbi.nlm.nih.gov/pubmed/35297119
http://dx.doi.org/10.1002/pds.5429
work_keys_str_mv AT gerhardtobias pandemicvaccinetestingcombiningconventionalandchallengestudies
AT strombrianl pandemicvaccinetestingcombiningconventionalandchallengestudies
AT eyalnir pandemicvaccinetestingcombiningconventionalandchallengestudies

Ejemplares similares